291 related articles for article (PubMed ID: 230492)
1. Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances.
Whitaker MO; Wyche A; Fitzpatrick F; Sprecher H; Needleman P
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5919-23. PubMed ID: 230492
[TBL] [Abstract][Full Text] [Related]
2. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
Needleman P; Whitaker MO; Wyche A; Watters K; Sprecher H; Raz A
Prostaglandins; 1980 Jan; 19(1):165-81. PubMed ID: 6247744
[TBL] [Abstract][Full Text] [Related]
3. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties.
Needleman P; Raz A; Minkes MS; Ferrendelli JA; Sprecher H
Proc Natl Acad Sci U S A; 1979 Feb; 76(2):944-8. PubMed ID: 218223
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
Haslam RJ; Davidson MM; Desjardins JV
Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
[TBL] [Abstract][Full Text] [Related]
5. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Heikes JE; Sprague PW; Antonaccio MJ
Prostaglandins; 1981 Aug; 22(2):295-307. PubMed ID: 6270744
[TBL] [Abstract][Full Text] [Related]
6. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
7. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect.
Remuzzi G; Benigni A; Dodesini P; Schieppati A; Livio M; De Gaetano G; Day SS; Smith WL; Pinca E; Patrignani P; Patrono C
J Clin Invest; 1983 Mar; 71(3):762-8. PubMed ID: 6298281
[TBL] [Abstract][Full Text] [Related]
8. PGD3 is the mediator of the antiaggregatory effects of the trienoic endoperoxide PGH3.
Whitaker MO; Needleman P; Wyche A; Fitzpatrick FA; Sprecher H
Adv Prostaglandin Thromboxane Res; 1980; 6():301-3. PubMed ID: 6966885
[No Abstract] [Full Text] [Related]
9. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides.
Di Minno G; Bertelé V; Cerletti C; de Gaetano G; Silver MJ
Thromb Res; 1982 Feb; 25(4):299-306. PubMed ID: 6803385
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin H2 directly lowers human platelet cAMP levels.
Rybicki JP; Le Breton GC
Thromb Res; 1983 Jun; 30(5):407-14. PubMed ID: 6310815
[TBL] [Abstract][Full Text] [Related]
11. Interrelation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3',5'-adenosine monophosphate in human blood platelets.
Salzman EW
Biochim Biophys Acta; 1977 Aug; 499(1):48-60. PubMed ID: 196670
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activation by collagen and 15-hydroxy-9 alpha,11 alpha-peroxidoprosta-5,13-dienoic acid (PGH2) of phosphatidylinositol metabolism and arachidonic acid release in human platelets.
Rittenhouse SE; Allen CL
J Clin Invest; 1982 Dec; 70(6):1216-24. PubMed ID: 6816811
[TBL] [Abstract][Full Text] [Related]
13. Regulatory role of cyclic adenosine 3',5'-monophosphate on the platelet cyclooxygenase and platelet function.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1979 Jan; 582(1):44-58. PubMed ID: 216415
[TBL] [Abstract][Full Text] [Related]
14. Cardiac and renal prostaglandin I2. Biosynthesis and biological effects in isolated perfused rabbit tissues.
Needleman P; Bronson SD; Wyche A; Sivakoff M; Nicolaou KC
J Clin Invest; 1978 Mar; 61(3):839-49. PubMed ID: 346605
[TBL] [Abstract][Full Text] [Related]
15. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
17. The effects of amrinone on human platelet aggregation: evidence that amrinone does not act through a cyclic nucleotide mechanism in platelet rich plasma.
Lippton HL; Horwitz PM; McNamara DB; Ignarro LJ; Landry AZ; Hyman AL; Kadowitz PJ
Prostaglandins Leukot Med; 1985 May; 18(2):193-204. PubMed ID: 3925461
[TBL] [Abstract][Full Text] [Related]
18. Mechanism underlying the inhibition of platelet aggregation by eicosapentaenoic acid and its metabolites.
Needleman P; Sprecher H; Whitaker MO; Wyche A
Adv Prostaglandin Thromboxane Res; 1980; 6():61-8. PubMed ID: 6247894
[No Abstract] [Full Text] [Related]
19. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
20. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
Lecompte T; Joussemet M; Hainaut J
Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
[No Abstract] [Full Text] [Related]
[Next] [New Search]
